- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
Dyspnea with ticagrelor use studied
Dyspnea Is commonly reported by coronary artery disease patients taking ticagrelor, but it did not appear to have a negative impact on cardiac or pulmonary function at 6-weeks follow-up, according to research.
J Am Coll Cardiol, 2010;56:185-193. [July 13, 2010]
Dyspnea is commonly reported by coronary artery disease (CAD) patients taking ticagrelor, but it did not appear to have a negative impact on cardiac or pulmonary function in these patients at six weeks follow-up, according to researchers from the University of Sheffield in the United Kingdom. They analyzed data from 123 patients with stable CAD taking aspirin and either ticagrelor, clopidogrel, or placebo. The researchers found that more patients in the ticagrelor group reported dyspnea than in the clopidogrel or placebo groups and three patients in the ticagrelor group discontinued the medication due to dyspnea. Eight of the 22 patients in the ticagrelor group experiencing dyspnea did so within 24 hours, and 17 did so within a week. No changes in cardiac or pulmonary functions were seen in any treatment group, including the patients on ticagrelor reporting dyspnea, from baseline through six weeks' follow-up.
